|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| First Author, Year | Country(TB Burdena) | % Male | Mean Age in Years (SD) | %HIV | % BCG | Other Study Population Comments | T-SPOT.*TB*Specificity(95% CI, Interval) (N) | QFT-GSpecificity(95% CI, Interval) (N) | QFT-GITSpecificity(95% CI, Interval) (N) | Quality Rating |
| Franken, 2007126 | Netherlands (L) | 91.8 | 19.6 (2.8) | NR | 8.8 | Population is Dutch armed forces recruits; 2 subjects were known to have been previously treated for TB.  |  |  | 0.97(0.93 to 0.99)(171) | Poor |
| Min, 201394 | South Korea (I) | 57.6 | Median: 28Range: 23 to 42 | NR | 75.6 | Data extracted for health volunteer study subjects with neither a history of TB treatment nor contact with active TB patients.  |  |  | 0.94(0.80 to 0.98)(33) | Poor (Sp)Fair (Sn) |
| Ozekinci, 2007103 | Turkey (I) | NR | 30Range: 17 to 61 | NR | 67.4b | Data extracted for subjects with no history of exposure to TB. | 0.89(0.73 to 0.96)(28) |  |  | Poor |
| Palazzo, 2008105 | Italy (L) | NR | 37 (2) | 0 | 21.0 | Data extracted for healthy control subjects.  |  | 0.94(0.72 to 0.99)(16) | 1.00(0.78 to 1.00)(14) | Poor |

a TB burden according to World Health Organization classification. (L) Low <10 cases/100,000; (I) Intermediate 10–99 cases/100,000; (H) High >100 cases/100,000.

b Represents demographics of the overall study population; demographics for subjects eligible for inclusion in analysis were not reported.

**Abbreviations:** BCG=bacille Calmette-Guérin; CI=confidence interval; HIV=human immunodeficiency virus; IGRA=interferon-gamma release assay; NR=not reported; QFT-G=QuantiFERON-TB Gold (2nd generation test); QFT-GIT=QuantiFERON-TB Gold In-Tube (3rd generation test); M.Tb=*Mycobacterium tuberculosis*; SD=standard deviation; Sn=sensitivity; Sp=specificity; TB=tuberculosis.